Thanks Taureanbull. Really appreciate your responses. So in essence , a phase 2 trial for Dementia and/or Parkinsons would have been much bigger in scale/cost than the 4 indications Neuren decided to move forward with, hence the reason it didnt go any further. I am really hoping money was the only reason for not moving forward, as the potential is amazing if the pre-clinicals get an opportunity to be proven (and is proven) via clinical trials.
The first set of phase 2 trial results have a lot hinging on it! Hopefully the Phelan-McDermid results are conclusive enough for all these other possibilities to become very relevant.
- Forums
- ASX - By Stock
- Ann: Neuren completes Phelan-McDermid syndrome Phase 2 trial
Thanks Taureanbull. Really appreciate your responses. So in...
-
- There are more pages in this discussion • 15 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add NEU (ASX) to my watchlist
|
|||||
Last
$15.48 |
Change
0.160(1.04%) |
Mkt cap ! $1.978B |
Open | High | Low | Value | Volume |
$15.10 | $15.48 | $15.04 | $6.154M | 402.1K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 1498 | $15.45 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$15.50 | 8296 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 1498 | 15.450 |
1 | 319 | 15.420 |
1 | 33 | 15.400 |
2 | 6322 | 15.370 |
1 | 5004 | 15.350 |
Price($) | Vol. | No. |
---|---|---|
15.500 | 8296 | 2 |
15.510 | 2291 | 1 |
15.540 | 2291 | 1 |
15.560 | 3500 | 1 |
15.570 | 2291 | 1 |
Last trade - 16.10pm 21/08/2024 (20 minute delay) ? |
Featured News
NEU (ASX) Chart |